Promise is currently asking interested readers to wait while it changes prescriber networks. The live sermorelin page says clinical visits are paused and that the email form is a notification request, not a medical assessment.
We checked that page on September 23, 2026, without submitting information or seeking treatment. CoreAge Rx is our featured commercial partner. This review does not report a patient experience or use commercial placement as evidence of better clinical care.
Promise is currently asking interested readers to wait while it changes prescriber networks. The live sermorelin page says clinical visits are paused and.
The pause is a service status, not a decision about you
The current Promise page describes sermorelin as coming soon. It explains that a network change has paused visits, while an email waitlist can notify readers if the treatment becomes available.
Being unable to start a visit during that pause does not mean a clinician has reviewed or rejected your history. Equally, joining a waitlist does not mean a clinician has accepted you. No prescription is issued from the notification form described on the page.
This distinction matters if you are comparing services because of a concern you want assessed soon. An unspecified reopening date cannot supply a reliable appointment plan. Continue discussing your needs with your existing healthcare team rather than postponing needed care around an uncertain notification.
What to expect from the information still on the page
Promise describes an intended process involving a health questionnaire, clinician review, and pharmacy dispensing when appropriate. Those descriptions explain the planned model. They do not establish that clinical visits, prescribing, or delivery are available today.
We have not verified a current purchasing price or reopening date. Older search results contain prices from an earlier page, but we have not carried those amounts into this review. A familiar product name and a visible description do not make an outdated offer current.
The Pallas Health review provides a different access example: a live advertised program with a published age boundary. The practical question for both services is whether the particular route is available and appropriate for you.
Prepare your questions without treating the waitlist as care
If you are interested in a future assessment, keep a short note of the concern you want addressed, its duration, your medication list, and relevant previous evaluations. Those notes are for a clinician when a real assessment is available; they do not belong in an email-only notification field.
Think about the conversation format you would need. You may want an opportunity to ask follow-up questions aloud, help reading a report, or a written explanation of the decision. Ask the reopened service whether those options exist rather than assuming the old website's arrangements will continue.
Our accessible-appointment guide and medication-list guide can help you organize that preparation. Neither tool determines whether sermorelin is the right treatment.
Recheck the clinical relationships after the transition
The Promise terms describe a technology platform and separate clinical and dispensing responsibilities. Because the product page now announces a prescriber-network change, earlier named relationships should not be treated as confirmed future assignments.
When visits reopen, ask who will assess you, where that clinician is licensed to provide care, and which pharmacy would dispense a prescription. Also ask how relevant information can be shared with your usual clinician with your permission.
A clear answer should identify who makes treatment decisions and who answers medication questions. We have not tested the new network, attended a visit, or verified an individual pharmacy assignment. Those details remain to be established when the service actually resumes.
A clinician may still recommend another path
If a future assessment becomes available, it should allow the clinician to request more information or decline prescribing. That is different from the present administrative pause. Our declined-prescription guide helps you ask for the reasoning and an appropriate next step.
Be accurate about age, symptoms, medicines, and past treatment. Do not remove information because you think it may reduce the chance of receiving a prescription. A useful consultation addresses the health concern rather than simply confirming the medicine you hoped to obtain.
The Endocrine Society's adult growth hormone deficiency guideline concerns a specific diagnosis and assessment. It does not turn common midlife symptoms into a reason for a particular compounded prescription.
Ask about the actual medicine and costs later
Once a concrete offer is available, obtain the selected plan's price, recurring charges, required tests or visits, and cancellation terms. Confirm the exact preparation and pharmacy rather than assuming older descriptions still govern the order.
The FDA's compounding explanation provides the separate reminder that compounded medicines are not FDA-approved. An orderly review process does not itself establish a benefit for an individual reader.
Our assessment today
Promise currently belongs in an availability watch, outside active-provider recommendations. We can verify the pause notice; we cannot verify a future appointment, current purchase price, or the outcome of a clinical conversation that has not occurred.
Read CoreAge Rx versus Promise for a comparison centered on that access difference. Choose the next clinical conversation around your actual needs and confirmed availability, not the assumption that an email notification will supply care on a particular date.
The source notes
Sources & further reading
Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Check the dated discussion in each article for the scope of our research; offers can change.